WO2001049246A3 - Sustained release tablet formulations comprising clarithromycin - Google Patents
Sustained release tablet formulations comprising clarithromycin Download PDFInfo
- Publication number
- WO2001049246A3 WO2001049246A3 PCT/TR2001/000002 TR0100002W WO0149246A3 WO 2001049246 A3 WO2001049246 A3 WO 2001049246A3 TR 0100002 W TR0100002 W TR 0100002W WO 0149246 A3 WO0149246 A3 WO 0149246A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clarithromycin
- sustained release
- release tablet
- release
- tablet formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36329/01A AU3632901A (en) | 2000-01-05 | 2001-01-04 | Sustained release tablet formulations comprising clarithromycin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2000/00054 | 2000-01-05 | ||
TR2000/00054A TR200000054A2 (en) | 2000-01-05 | 2000-01-05 | Sustained-release tablet formulations containing clarithromycin. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001049246A2 WO2001049246A2 (en) | 2001-07-12 |
WO2001049246A3 true WO2001049246A3 (en) | 2002-08-15 |
Family
ID=21622322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2001/000002 WO2001049246A2 (en) | 2000-01-05 | 2001-01-04 | Sustained release tablet formulations comprising clarithromycin |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3632901A (en) |
TR (1) | TR200000054A2 (en) |
WO (1) | WO2001049246A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1285659E (en) * | 2001-08-13 | 2007-10-09 | Fond Salvatore Maugeri Clinica | Use of clarithromycin compositions in the manufacture of a medicament for the treatment of arthritis deformans |
US6642276B2 (en) * | 2001-10-01 | 2003-11-04 | M/S Ind-Swift Limited | Controlled release macrolide pharmaceutical formulations |
WO2005082331A2 (en) * | 2004-02-26 | 2005-09-09 | Ranbaxy Laboratories Limited | Extended release tablets of clarithromycin |
EP2283824B1 (en) | 2009-07-30 | 2017-04-19 | Special Products Line S.p.A. | Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0967256A (en) * | 1995-08-31 | 1997-03-11 | Taisho Pharmaceut Co Ltd | Drug for common cold |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
WO2000048607A1 (en) * | 1999-02-19 | 2000-08-24 | LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
-
2000
- 2000-01-05 TR TR2000/00054A patent/TR200000054A2/en unknown
-
2001
- 2001-01-04 WO PCT/TR2001/000002 patent/WO2001049246A2/en active Application Filing
- 2001-01-04 AU AU36329/01A patent/AU3632901A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0967256A (en) * | 1995-08-31 | 1997-03-11 | Taisho Pharmaceut Co Ltd | Drug for common cold |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
WO2000048607A1 (en) * | 1999-02-19 | 2000-08-24 | LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 9720, Derwent World Patents Index; AN 1997-221692, XP002176786, "Remedies for colds- comprise ibuprofen and/or acetaminophen and clarithromycin" * |
Also Published As
Publication number | Publication date |
---|---|
TR200000054A2 (en) | 2001-08-21 |
AU3632901A (en) | 2001-07-16 |
WO2001049246A2 (en) | 2001-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1046244A1 (en) | Controlled release and taste masking oral pharmaceutical compositions. | |
CA2232450A1 (en) | Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole | |
CA2199778A1 (en) | Extended release formulation of venlafaxine | |
WO2000041681A3 (en) | MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST | |
EP1135173A4 (en) | A medicinal aerosol formulation | |
WO2000019985A3 (en) | New sustained release oral formulations | |
CA2395231A1 (en) | Hydrogel-driven layered drug dosage form | |
EP2033648A3 (en) | Sustained release drug delivery system containing prodrugs | |
HUP0102206A2 (en) | Delavirdine tablet formulation | |
WO2002045571A3 (en) | Fast dissolving tablet | |
MXPA03008062A (en) | Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent. | |
WO2007052125A3 (en) | Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent | |
NZ504460A (en) | Sustained release formulations containing venlafaxine | |
MY127350A (en) | Flash-melt oral dose formulations | |
WO2005007137A8 (en) | Tablets containing ambroxol | |
WO2001049246A3 (en) | Sustained release tablet formulations comprising clarithromycin | |
AU1244199A (en) | Tablets to be crunched or sucked, comprising iron as active principle | |
WO2007016350A3 (en) | Modified release tablet formulations with enhanced mechanical properties | |
FI963567A (en) | The diclofenacs containing prolonged-release tablets | |
MY133230A (en) | Combination of no synthase inhibitor(s) and metabolic antioxidant(s) | |
AU3706999A (en) | Controlled release tablet produced from linear water-insoluble polysaccharides | |
MXPA01008348A (en) | Microcapsules for sustained release of drugs. | |
WO2003020265A3 (en) | Compositions comprising pectin and ascorbic acid | |
AU2540499A (en) | Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content | |
AU9585301A (en) | A compacted 2,2-dibromo-3-nitrilopropionamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |